Clinical Decision Support
Oncology Analytics’ Approach to Benefits Management and Clinical Decision Support
Recently, the American Society of Clinical Oncology (ASCO) has published recommended guidelines for chemotherapy utilization management companies. OA supports and adheres to these recommendations. In particular, OA has always believed in transparency in the development of a chemotherapy rating system. In order to create even greater transparency and to assist treating physicians to promptly identify the best treatments for their patients, OA has developed a proprietary “Clinical Decision Support” tool. This tool enables medical oncologists to sort all available chemotherapy options based on the parameters most important to them and their patients. Thus, if efficacy is of primary importance, followed by toxicity and cost, then medical oncologists and their patients can determine the best approach. Additional treatment (“protocol”) search filters include the risk of infection, risk of nausea and vomiting, genetic and molecular testing results, performance status, line of therapy and others.
Since its inception in 2009, Oncology Analytics (OA) has promoted high quality and cost effective chemotherapy. This is accomplished by carefully evaluating and rating all available treatments for efficacy, toxicity and cost. After a protocol is evaluated, it is placed into one of OA’s unique categories.